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Monocyte-chemotactic-protein-1 (MCP-1) plays vital roles in immune response, angiogenesis, and pregnancy outcome. We in-
vestigated plasma MCP-1 concentrations in 40 mothers and their 20 intrauterine-growth-restricted (IUGR) and 20 appropriate-
for-gestational-age (AGA) fetuses and neonates on postnatal days 1 (N1) and 4 (N4). Maternal and fetal MCP-1 concentrations
were decreased (P<001 and P = .018, resp.), whereas N1 MCP-1 concentrations were elevated in IUGR group (P = .012). In both
groups, fetal MCP-1 concentrations were lower compared to N1 and N4 ones (P = .045, P = .012, resp., for AGA, P<.001 in each
case for IUGR). Reduced maternal and fetal MCP-1 concentrations in IUGR may reﬂect failure of trophoblast invasion, suggesting
that down-regulation of MCP-1 may be involved in the pathogenesis of IUGR. Increased MCP-1 concentrations in IUGR neonates
and higher postnatal ones in all infants may be attributed to gradual initiation of ex utero angiogenesis, which is possiblyenhanced
in IUGR.
Copyright © 2007 Despina D. Briana et al. This is an open access article distributed under the Creative Commons Attribution




nancy is dependent on a delicate interaction between the en-
docrine and immune systems [1]. Disturbance of this bal-
ance can result in a wide range of abnormalities including
intrauterine growth restriction (IUGR) [2].
Cytokines, the local eﬀectors of the immune system, are
increasingly thought to play a key role during pregnancy
[1, 3]. Chemokines, a subset of cytokines, speciﬁc in their
ability to attract and activate immune cells, are thought to
play pivotal roles in the immune recognition, maintenance
ofpregnancy,andparturition[4].Inthisrespect,unbalanced
chemokine expression may contribute to defective placenta-
tion and pregnancy failures [3].
Monocyte chemotactic protein (MCP)-1 is a 76-amino
acid β chemokine, which is secreted by a wide range
of cell types, including monocytes [5], macrophages [6],
lymphocytes [7], and endothelial cells [8]. It primarily
serves as a chemotactic factor that attracts and activates
monocytes/macrophages into cites of inﬂammation, by in-
ducing leukocyte-endothelial cell adhesion and promoting
transendothelial migration [6, 9]. Recently, a number of
other functions have been ascribed to MCP-1, including
that of an angiogenic factor [10, 11]. Moreover, MCP-1
expression has been demonstrated in maternal gestational
tissues, such as decidua and myometrium, as well as in
embryonically-derived ones, including chorion and placenta
[4]. MCP-1 production increases during normal pregnancy,
andevenmoreduringlabor,suggestingthatMCP-1mayplay
a role, which is more important as pregnancy advances, by
locally modulating the immune system at the level of pe-
ripheral leukocytes [1]. However, the perinatal expression of
MCP-1 has not been, up to the present, investigated in IUGR
pregnancies.
In this respect, this study was based on the hypothesis
that circulating concentrations of MCP-1 might diﬀer be-
tween IUGR cases and appropriate for gestational age (AGA)
controls, since the former are characterized by abnormal im-
mune responses, leading to inappropriate cytokine secre-
tion [12, 13], and impaired angiogenesis [14–17]. There-
fore, we aimed to evaluate and compare, for the ﬁrst time
to our knowledge, plasma MCP-1 concentrations in IUGR
and AGA mother/infant pairs at crucial perinatal time points2 Mediators of Inﬂammation
and investigate the association of its circulating concentra-
tions with gender, parity, mode of delivery and, adjusted
birth weight (customized centiles).
2. MATERIALS AND METHODS
The Ethics Committee of our teaching hospital approved the
study protocol. All included mothers provided signed in-
formed consent before recruitment. Forty parturients giv-
ing consecutively birth, either to 20 AGA or 20 asymmetric
IUGR full-term singleton infants (birth weight ≤ 3rd cus-
tomized centile), were included in the study. The gestation-
relatedoptimalweightcomputer-generatedprogram[18,19]
was used to calculate the customized centile for each preg-
nancy, taking into consideration signiﬁcant determinants of
birthweight,suchasmaternalheight,bookingweight,ethnic
group, parity, gestational age, and gender [18]. Gestational
age was estimated using the date of the last menstrual period
and early antenatal ultrasound. Birth weight was measured
with an electronic scale.
Nine of the 20 mothers with IUGR oﬀspring presented
withpreeclampsia[20].Theremaining11motherspresented
with pregnancy-induced hypertension and in addition, suf-
fered from iron-deﬁcient anemia (3 cases), gestational dia-
betes mellitus (2 cases), hypothyroidism (3 cases), extreme
obesity (2 cases), and cardiac arrhythmias (1 case). Five of
the above women were smoking >10 cigarettes/day during
the whole duration of pregnancy.
Doppler studies were performed in the IUGR group ev-
ery 10–15 days, starting from the 32nd gestational week.
During each Doppler velocimetry evaluation, three consec-
utive measurements of the pulsatility index (PI) of the stud-
ied vessel (uterine, umbilical, cerebral arteries) were done,
and the mean value was recorded. Concerning uterine and
u m b i l i c a la rt e ri e s[ 21, 22], mean PI values were progressively
found to be in the upper physiological limits for the corre-
sponding gestational age in 13 cases (ranging between the
90th and the 95th percentile) while in the remaining seven
cases PI values showed increased impedance to ﬂow, being
above the 95th percentile for gestational age. Regarding mid-
dle cerebral arteries [23], Doppler studies showed resistance
to be in the lower physiological limits for gestational age, in-
dicatingtheinitiationofbloodﬂowredistributionprocess,in
order to spare vital organs (brain, heart, and adrenals). Nev-
ertheless, amniotic ﬂuid was diminished in all IUGR cases.
For the evaluation of the amniotic ﬂuid, the largest ﬂuid col-
umn on the vertical plane was assessed and was deﬁned as
diminished, if <2cm. Placental weights were reduced rang-
ing from 255 to 400g.
In the AGA group, mothers were healthy and were either
nonsmokers or abstained from smoking during pregnancy.
Placentas were normal in appearance and weight.
Testsforcongenitalinfectionswerenegativeinallwomen
of both groups, and their oﬀspring had no symptoms of in-
trauterine infection or signs of genetic syndromes. One- and
ﬁ v e - m i n u t eA p g a rs c o r e sw e r ei na l lc a s e sa n dc o n t r o l s≥ 8.
All neonates were breastfed. Demographic data of participat-
ing subjects are listed in Table 1.
Blood was collected in pyrogen-free tubes from the fol-
lowing: (i) the mothers during the ﬁrst stage of labor, or be-
fore receiving anesthesia in cases of elective caesarean sec-
tion;(ii)theumbilicalcordsafterdoubleclamping,reﬂecting
fetal state; and (iii) the neonates before feeding on postpar-
tum days 1 (N1) and 4 (N4), characterizing transition and
stabilizationtoextrauterinelife,respectively.Plasmawassep-
arated by centrifugation and was kept frozen at −80
◦C until
assay.
The determination of plasma MCP-1 concentrations was
performed by ELISA (MCP-1 (Human) ELISA Kit, HBT
(HyCult Biotechnology b.v) UDEN, the Netherlands). The
minimumdetectableconcentration,intra-andinterassayco-
eﬃcients of variation were <10pg/mL, 6.2% and 7.7%, re-
spectively.
3. STATISTICAL ANALYSIS
MCP-1 data were normally distributed (Kolmogorov-
Smirnov test); thus, parametric tests (Anova for repeated
measures, paired samples t-test with Bonferroni correction
for multiple comparisons) were applied in the analysis.
Spearman’s or Pearson’s correlation coeﬃcients, where ap-
propriate, were used to detect any positive or negative corre-
lations. P < .05 was considered statistically signiﬁcant.
4. RESULTS
Determined mean (95% conﬁdence intervals (CI)) values of
circulating MCP-1 concentrations in both groups are shown
in Figure 1.
Maternal and fetal MCP-1 concentrations were signiﬁ-
cantly decreased in the IUGR compared to the AGA group
afteradjustingformultiplecomparisons(b:167.018,95%CI:
114.511–219.525, P < .001 and b: 216.322, 95% CI: 40.423–
392.221, P = .018, resp.). On the contrary, N1 MCP-1 con-
centrations were signiﬁcantly elevated in the IUGR com-
pared to the AGA group after adjusting for multiple com-
parisons ((b: −467.934, 95% CI: −824.383−(−111.484), P =
.012).
In the AGA group, maternal MCP-1 concentrations were
signiﬁcantly lower compared to fetal, N1 and N4 ones (P =
.019, P = .001, and P < .001, resp.) while fetal MCP-1 con-
centrations were signiﬁcantly lower compared to N1 and N4
ones (P = .045 and P = .012, resp.).
In the IUGR group, maternal MCP-1 concentrations
were signiﬁcantly lower compared to fetal, N1 and N4 ones
(P = .003, P < .001 and P < .001, resp.) while fetal MCP-
1 concentrations were signiﬁcantly lower compared to N1
and N4 ones (P < .001 in each case). Finally, in each
(IUGR or AGA) group, the eﬀect of gender, mode of de-
livery, and parity on plasma MCP-1 concentrations was not
signiﬁcant.
5. DISCUSSION
During gestation, inﬂammatory cytokines, occasionally
more abundant than growth-promoting ones, lead via di-
rect or indirect eﬀects to IUGR [24]. In this respect, manyDespina D. Briana et al. 3
Table 1: Demographic data for AGA and IUGR neonates and their mothers.
AGA IUGR P
Mean (SD) Mean (SD)
Birthweight (g) 3356 (223) 2342 (229) <.001
Birthweight centile 65.4 (12.6) 1.5 (1.5) <.001
Gestational age (weeks) 38.4 (1.0) 37.8 (1.0) <.024
Gender NS
Male 11 (55%) 11 (55%)
Female 9 (45%) 9 (45%)
Maternal age (years) 28 (4.0) 31 (5.0) NS
Parity NS
Primigravida 10 (50%) 11 (55%)
Other 10 (50%) 9 (45%)
Mode of delivery <.013
Vaginal 13 (65%) 8 (40%)
Cesarean section 7 (35%) 12 (60%)
recent studies point to altered cytokine pattern in IUGR
pregnancies, documenting up- or downregulation of sev-
eral cytokines in amniotic ﬂuid, as well as maternal and fe-
tal circulation [2, 12, 25–30]. Thus, elevated TNF-alpha and
reduced interleukin (IL)-1 beta amniotic ﬂuid concentra-
tions [2], as well as enhanced placental TNF-alpha secre-
tion [31], have been implicated in vasoconstriction of the
feto-placental vascular bed, resulting in IUGR. Furthermore,
elevated maternal TNF-alpha, IL-6 [2, 25], IL-8 [25], and
macrophage colony-stimulating factor [26] concentrations
have been observed in IUGR due to placental insuﬃciency.
On the other hand, reduced placental IL-6 production has
been associated with placental ischemia and failure of fetal
growth in pregnancy-induced hypertension [27]. Similarly,
reduced placental IL-10 expression has been involved in the
pathogenesis of IUGR [32].
In line with these reports, the results of the present study
indicate that circulating maternal and fetal MPC-1 concen-
trations are signiﬁcantly lower in IUGR cases compared to
AGA controls. Successful placentation involves the develop-
mentofahighﬂowuteroplacentalcirculation,whichisestab-
lishedbytrophoblastinvasionandtransformationofthema-
ternal intramyometrial portion of the spiral arterioles [33].
Asymmetric fetal growth restriction is attributed to reduced
placental blood ﬂow with subsequent impaired fetomaternal
exchangeofsubstrates,aprocessprobablyinitiatedbyunsuc-
cessful transformation of uteroplacental spiral arteries [34].
In this respect, Brosens et al. showed that the expected phys-
iological changes in pregnancy are restricted in the decidual
segmentsoftheuteroplacentalarteriesinallhypertensivepa-
tients with IUGR oﬀspring [35]. This failure of placentation
h a sb e e na t t r i b u t e dt oi n a d e q u a t ed e c i d u a lc e l l u l a ri m m u -
nity, limiting trophoblastic invasion [34]. Thus, it has been
hypothesized that placental insuﬃciency in IUGR could be
caused by an immunological phenomenon [12].
MCP-1, abundantly produced during gestation by en-
dometrial, myometrial, placental, and trophoblast cell types
[4], has been reported to play speciﬁc roles in endome-
trial angiogenesis, apoptosis, proliferation, and diﬀerenti-
ation [3]. Furthermore, MCP-1 plays an essential role in
maintaining pregnancy [1, 4]. Based on these facts, we spec-
ulate that MCP-1 may regulate trophoblast invasion into the
placental bed and may inﬂuence placental development and
function by acting via decidual and fetal macrophages, as
previously stated for macrophage colony-stimulating factor
[36]. Thus, the lower maternal and fetal MCP-1 concentra-
tions in our IUGR cohort may indicate failure of trophoblast
invasion, suggesting that downregulation of MCP-1 may be
involved in the pathogenesis of IUGR.
Controversial data exist in the literature, regarding cir-
culating MCP-1 concentrations in preeclampsia. Thus, a re-
cent study demonstrated signiﬁcantly elevated MCP-1 con-
centrations in preeclamptic patients [37], whereas other re-
searchers found no signiﬁcant diﬀerences in plasma MCP-
1 concentrations between preeclamptic and normal preg-
nant women [38]. In the former study [37], it has been
hypothesized that, in preeclampsia, the damaged endothe-
lial cells and/or inﬁltrated macrophages may produce MPC-
1, which probably promotes extension of the lesions. A
possible explanation for our contradictory ﬁnding may re-
late to the fact that more than half of the women with
IUGR oﬀspring in our study presented with pregnancy-
induced hypertension, which is not associated with endothe-
lial dysfunction [39] and thus, with probably higher MCP-1
production.
On the other hand, our study demonstrated increased
circulating MCP-1 concentrations in IUGR neonates com-
pared to AGA controls, as well as higher postnatal concen-
trations in all included infants. MCP-1 has been reported to
directly promote angiogenesis, as a consequence of leuko-
cyte inﬁltration, or growth factor expression [40]. There-
fore, above ﬁndings may be attributed to a gradual initia-
tion of ex utero angiogenesis, a prerequisite for tissue growth
and development [41], which is possibly enhanced in IUGR
cases, due to a potential initiation of the catch-up growth
process [42]. In addition, the reported higher fetal MCP-14 Mediators of Inﬂammation
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Figure 1: MCP-1 concentrations in the plasma of mothers (MS),
fetuses (UC), and neonates on day 1 (N1) and 4 (N4) postpartum
in appropriate for gestational age (AGA) and intrauterine growth
restricted (IUGR) groups. Bars represent the mean values and error
bars one SD of the mean.
concentrations compared to respective maternal ones may
be attributed to the fact that, in late gestation, MCP-1 is
predominantly released by embryonically derived tissues, in-
cluding the chorion and the placenta [4].
Finally, gender, parity, and the mode of delivery did not
prove to have a signiﬁcant eﬀect on circulating MCP-1 con-
centrations in this study. Relatively, a recent report docu-
mented signiﬁcantly higher MCP-1 concentrations in the
placentas of primigravidas [24]. Furthermore, amniotic ﬂuid
concentrations of MCP-1 reportedly increase during spon-
taneous labour, suggesting its potential role in this process
[43].
In conclusion, the reduced maternal and fetal MCP-
1 concentrations in our IUGR cohort may reﬂect failure
of trophoblast invasion, suggesting that downregulation of
MCP-1maybeinvolved inthepathogenesisofIUGR.Onthe
other hand, the increased MCP-1 concentrations in IUGR
neonates, as well as the higher postnatal concentrations in
all included infants may be attributed to a gradual initiation
ofexuteroangiogenesis,whichispossiblyenhancedinIUGR
cases. Additional studies are required to elucidate the physi-
ological role of this chemokine in both normal and compli-
cated pregnancies.
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